PMID- 37720446
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230919
IS  - 2078-6891 (Print)
IS  - 2219-679X (Electronic)
IS  - 2078-6891 (Linking)
VI  - 14
IP  - 4
DP  - 2023 Aug 31
TI  - Addition of transarterial chemoembolization improves outcome of tyrosine kinase 
      and immune checkpoint inhibitors regime in patients with unresectable 
      hepatocellular carcinoma.
PG  - 1837-1848
LID - 10.21037/jgo-23-486 [doi]
AB  - BACKGROUND: Transarterial chemoembolization (TACE) is the standard treatment for 
      hepatocellular carcinoma (HCC); the value of its combination with systemic 
      therapy is worthy of further exploration. This study aimed to investigate the 
      efficacy and safety of TACE combined with tyrosine kinase inhibitor (TKI) and 
      immune checkpoint inhibitor (ICI) in the treatment of unresectable HCC. METHODS: 
      In this retrospective observational, single-center study, 147 patients with 
      unresectable HCC were divided into a TACE group (n=98) and a non-TACE group 
      (n=49) based on whether TACE was performed during TKI plus ICI therapy. The 
      survival outcomes and adverse events (AEs) of the two groups were compared. 
      RESULTS: Data from patients with unresectable HCC who received TKI plus ICI 
      treatment between July 2017 and April 2020 were collected. The median 
      intrahepatic tumor size was 8.7 cm [interquartile range (IQR), 5.9-12.4 cm]. At 
      data cut-off, overall survival (OS) of the TACE group was significantly longer 
      than that of the non-TACE group (19.5 and 10.8 months, respectively, P=0.005). In 
      the high-risk cohort (with main or contralateral portal vein tumor thrombi and/or 
      bile duct invasion and/or a tumor burden >50% of liver), the OS of the TACE group 
      was still longer than that of the non-TACE group (14.9 and 8.7 months, 
      respectively, P=0.031). Major AEs were tolerated in both groups, and there was no 
      significant difference in their incidence (34.7% and 30.6%, respectively, 
      P=0.621). CONCLUSIONS: TACE treatment combined with TKI plus ICI regime resulted 
      in longer OS than treatment with TKI plus ICI alone for patients with 
      unresectable HCC.
CI  - 2023 Journal of Gastrointestinal Oncology. All rights reserved.
FAU - Hu, Yue
AU  - Hu Y
AD  - Department of Interventional Radiology, The Third Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
AD  - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer 
      Center, Guangzhou, China.
FAU - Pan, Tao
AU  - Pan T
AD  - Department of Interventional Radiology, The Third Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
FAU - Cai, Xi
AU  - Cai X
AD  - Department of Interventional Radiology, The Third Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
AD  - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer 
      Center, Guangzhou, China.
FAU - He, Quan-Sheng
AU  - He QS
AD  - Department of Interventional Radiology, The Third Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
FAU - Zheng, Yu-Bao
AU  - Zheng YB
AD  - Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Huang, Ming-Sheng
AU  - Huang MS
AD  - Department of Interventional Radiology, The Third Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
FAU - Jiang, Zai-Bo
AU  - Jiang ZB
AD  - Department of Interventional Radiology, The Third Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
FAU - Chen, Jun-Wei
AU  - Chen JW
AD  - Department of Interventional Radiology, The Third Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
FAU - Wu, Chun
AU  - Wu C
AD  - Department of Interventional Radiology, The Third Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20230814
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC10502547
OTO - NOTNLM
OT  - Hepatocellular carcinoma (HCC)
OT  - combination therapy
OT  - immune checkpoint inhibitor (ICI)
OT  - transarterial chemoembolization (TACE)
OT  - tyrosine kinase inhibitor (TKI)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jgo.amegroups.com/article/view/10.21037/jgo-23-486/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2023/09/18 06:42
MHDA- 2023/09/18 06:43
PMCR- 2023/08/31
CRDT- 2023/09/18 04:40
PHST- 2023/06/07 00:00 [received]
PHST- 2023/08/01 00:00 [accepted]
PHST- 2023/09/18 06:43 [medline]
PHST- 2023/09/18 06:42 [pubmed]
PHST- 2023/09/18 04:40 [entrez]
PHST- 2023/08/31 00:00 [pmc-release]
AID - jgo-14-04-1837 [pii]
AID - 10.21037/jgo-23-486 [doi]
PST - ppublish
SO  - J Gastrointest Oncol. 2023 Aug 31;14(4):1837-1848. doi: 10.21037/jgo-23-486. Epub 
      2023 Aug 14.